Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Dickinson Andrew D | Chief Financial Officer | Nov 29 '24 | Option Exercise | 70.50 | 248,645 | 17,528,577 | 387,564 | Dec 03 02:43 PM | | Dickinson Andrew D | Chief Financial Officer | Nov 29 '24 | Sale | 92.76 | 248,645 | 23,065,271 | 138,919 | Dec 03 02:43 PM | | Parsey Merdad | Chief Medical Officer | Nov 27 '24 | Option Exercise | 62.44 | 145,413 | 9,079,689 | 245,012 | Nov 29 08:10 PM | | Parsey Merdad | Chief Medical Officer | Nov 27 '24 | Sale | 91.92 | 164,211 | 15,094,013 | 80,801 | Nov 29 08:10 PM | | ANDREW DICKINSON | Officer | Nov 29 '24 | Proposed Sale | 92.76 | 248,645 | 23,065,258 | | Nov 29 02:35 PM | | Bluestone Jeffrey | Director | Nov 26 '24 | Option Exercise | 61.24 | 10,000 | 612,442 | 15,708 | Nov 27 06:14 PM | | Bluestone Jeffrey | Director | Nov 26 '24 | Sale | 91.39 | 6,788 | 620,356 | 8,920 | Nov 27 06:14 PM | | MERDAD V PARSEY | Officer | Nov 27 '24 | Proposed Sale | 91.92 | 164,211 | 15,094,008 | | Nov 27 04:15 PM | | Bluestone Jeffrey | Director | Nov 26 '24 | Proposed Sale | 91.39 | 6,788 | 620,356 | | Nov 26 07:31 PM | | Mercier Johanna | Chief Commercial Officer | Nov 06 '24 | Sale | 91.28 | 5,000 | 456,400 | 73,127 | Nov 07 04:38 PM | | Parsey Merdad | Chief Medical Officer | Nov 06 '24 | Option Exercise | 57.92 | 25,000 | 1,448,000 | 125,189 | Nov 07 04:32 PM | | Parsey Merdad | Chief Medical Officer | Nov 06 '24 | Sale | 91.50 | 25,590 | 2,341,485 | 99,599 | Nov 07 04:32 PM | | MERDAD V PARSEY | Officer | Nov 06 '24 | Proposed Sale | 91.50 | 25,590 | 2,341,485 | | Nov 06 04:19 PM | | JOHANNA MERCIER | Officer | Nov 06 '24 | Proposed Sale | 91.28 | 5,000 | 456,400 | | Nov 06 04:07 PM | | Parsey Merdad | Chief Medical Officer | Oct 01 '24 | Sale | 83.83 | 2,000 | 167,660 | 100,189 | Oct 02 04:58 PM | | MERDAD V PARSEY | Officer | Oct 01 '24 | Proposed Sale | 83.83 | 2,000 | 167,660 | | Oct 01 04:27 PM | | Parsey Merdad | Chief Medical Officer | Sep 12 '24 | Option Exercise | 57.92 | 25,000 | 1,448,000 | 123,435 | Sep 13 07:07 PM | | Parsey Merdad | Chief Medical Officer | Sep 12 '24 | Sale | 84.50 | 21,246 | 1,795,287 | 102,189 | Sep 13 07:07 PM | | Mercier Johanna | Chief Commercial Officer | Sep 12 '24 | Sale | 83.78 | 29,357 | 2,459,577 | 78,127 | Sep 13 05:08 PM | | MERDAD V PARSEY | Officer | Sep 12 '24 | Proposed Sale | 84.50 | 21,246 | 1,795,287 | | Sep 12 04:45 PM | | JOHANNA MERCIER | Officer | Sep 12 '24 | Proposed Sale | 83.78 | 29,357 | 2,459,577 | | Sep 12 04:43 PM | | Mercier Johanna | Chief Commercial Officer | Aug 28 '24 | Sale | 78.03 | 9,513 | 742,299 | 105,466 | Aug 29 03:23 PM | | JOHANNA MERCIER | Officer | Aug 28 '24 | Proposed Sale | 78.03 | 9,513 | 742,299 | | Aug 28 04:18 PM | | Mercier Johanna | Chief Commercial Officer | Aug 13 '24 | Sale | 73.98 | 5,490 | 406,150 | 114,979 | Aug 14 02:23 PM | | JOHANNA MERCIER | Officer | Aug 13 '24 | Proposed Sale | 73.98 | 5,490 | 406,150 | | Aug 13 04:27 PM | | Parsey Merdad | Chief Medical Officer | Jul 01 '24 | Sale | 68.63 | 2,000 | 137,260 | 96,380 | Jul 01 08:06 PM | | GILEAD SCIENCES, INC. | 10% Owner | Apr 02 '24 | Buy | 0.76 | 485,250 | 368,790 | 7,345,473 | Apr 03 06:50 PM | | Parsey Merdad | Chief Medical Officer | Apr 01 '24 | Sale | 72.96 | 2,000 | 145,920 | 96,304 | Apr 02 06:38 PM | | Parsey Merdad | Chief Medical Officer | Feb 29 '24 | Sale | 72.74 | 8,230 | 598,624 | 92,706 | Feb 29 06:35 PM | | Parsey Merdad | Chief Medical Officer | Feb 28 '24 | Sale | 73.18 | 2,000 | 146,360 | 100,936 | Feb 29 06:35 PM | | GILEAD SCIENCES, INC. | 10% Owner | Feb 12 '24 | Buy | 22.00 | 910,000 | 20,020,000 | 4,126,119 | Feb 13 05:48 PM | | GILEAD SCIENCES, INC. | 10% Owner | Jan 29 '24 | Buy | 21.00 | 15,238,095 | 319,999,995 | 30,061,124 | Jan 31 05:00 PM | | Dickinson Andrew D | Chief Financial Officer | Jan 16 '24 | Sale | 85.78 | 5,000 | 428,900 | 101,534 | Jan 17 06:01 PM | | Mercier Johanna | Chief Commercial Officer | Jan 09 '24 | Sale | 85.23 | 8,242 | 702,466 | 82,729 | Jan 10 03:58 PM |
|
